Skip to content
Home/Companies/Biotech/InnoSkel

InnoSkel

Biotech·France·Exited 2024·Held 4yr
Entry
2020
Hold
4yr
Exit
2024

Who owns InnoSkel?

InnoSkel is a French Biotech company, formerly owned by Jeito Capital, exited in 2024. No current private equity owner is on file.

Hand-verified · updated 2026-09-30

Open JSON · CC-BY
Jeito Capital
Investor
Jeito Capital
Jeito I · 2021 · VC

Key facts

HQFrance
SectorBiotech
Exit Year
2024

More from Jeito I

Other portfolio companies in the same fund.

Corteria Pharmaceuticals
Corteria Pharmaceuticals
Active
BiotechFrance· 2023
Noema Pharma
Noema Pharma
Active
BiotechSwitzerland· 2023
Advesya
Advesya
Active
BiotechSpain· 2022
CatalYm
CatalYm
Active
BiotechGermany· 2022
CDR-Life
CDR-Life
Active
BiotechSwitzerland· 2022
EyeBio
Exited 2024
BiotechUS· 2022
to Merck

More PE-backed in Biotech

Comparable biotech deals from other GPs.

Abbisko Healthcare
Active
The Carlyle GroupChina
Adagene
Active
General AtlanticChina
Advanced Cell Diagnostics
Active
Summit PartnersUS
Akero Therapeutics
Akero Therapeutics
Active
General AtlanticUS
Aldevron
Aldevron
Active
TA AssociatesUS
Alloy Therapeutics
Alloy Therapeutics
Active
Mubadala CapitalUS

Questions

Who owns InnoSkel?

InnoSkel was formerly owned by Jeito Capital, exited in 2024. No current private equity owner is on file.

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue